AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 6 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Researchers working in the United States and Brazil have confirmed the effectiveness of Mtb 8.4, a low-molecular-weight immunoreactive T cell antigen, against challenge with tuberculosis infection in mice.
"Mounting evidence suggests that protective immunity to M. tuberculosis relies on both MHC class II-restricted CD4(+) T cells and MHC class I-restricted CD8(+) T cells," noted R.N. Coler, Infectious Disease Research Institute, Seattle, and researchers at the University of Pittsburgh and the Medical School of Itajuba, Brazil.
Mtb 8.4 appears to do just that, according to their findings, published in the Journal of Immunology.
Coller's work had already shown that Mtb 8.4, the result of purifying polypeptides in the culture filtrate of M. tuberculosis, elicited strong T cell responses in human peripheral blood mononuclear cells (PBMC) and in mice immunized with recombinant Mtb 8.4.
Here, they demonstrated that mice immunized with the current live attenuated vaccine, Mycobacterium bovis-bacillus Calmette-Guerin, and those infected intravenously with M. tuberculosis, produced Mtb 8.4-specific T cells.
When Coller and team immunized mice with plasmid DNA encoding Mtb 8.4 or Mtb 8.4 recombinant protein formulated with incomplete Freund's ...